原发恶性骨肿瘤患者首次翻修后假体再发并发症的可能性及危险因素
本研究回顾性分析817例长骨原发恶性骨肿瘤行大段假体置换患者,其中260例发生首次假体并发症,排除26例截肢后,234例中49%发生第二次并发症,中位时间17个月。二次翻修生存率2年69%、5年46%,总骨/全膝关节重建、术后放疗及糖尿病与二次并发症风险升高相关。
要点
- 首次翻修后二次并发症发生率高,5年无二次翻修生存率仅46%。
- 全骨/全膝关节重建较单关节置换二次翻修风险更高(HR 2.072)。
- 术后放疗及糖尿病是二次并发症的危险因素,术前放疗未显示关联。
核心结论
- 首次假体并发症翻修后二次并发症风险高,且多发生在首次翻修后较短时间内。
- 全骨/全膝关节重建、术后放疗及糖尿病与二次翻修风险升高相关。
- 建议规律骨科随访,并尽可能选择术前而非术后放疗。
研究设计与样本
- 回顾性队列研究,1993至2015年817例长骨肿瘤切除后采用单一设计大段假体系统重建。
- 75%(616/817)为骨肉瘤;599例可评估患者中260例(43%)发生首次假体并发症。
主要发现
- 234例中115例(49%)发生第二次并发症,中位时间17个月(IQR 5-48)。
- 首次与第二次并发症发生时间无差异(中位16个月 vs 17个月,p=0.976)。
- 二次翻修生存率2年69%(95%CI 63-76),5年46%(95%CI 38-53)。
- 第二次并发症最常见为感染39%(45/115),其次为结构并发症35%(40/115)。
- 全骨/全膝关节重建二次翻修风险升高(HR 2.072,95%CI 1.066-3.856,p=0.031)。
关键数值与推荐
- 术后放疗者二次并发症风险升高(HR 1.849,95%CI 1.092-3.132,p=0.022)。
- 术前放疗未显示与二次并发症风险相关(HR 1.174,95%CI 0.505-2.728,p=0.709)。
- 初次手术时糖尿病者二次翻修风险升高(HR 4.868,95%CI 1.497-15.823,p=0.009)。
- 首次并发症类型与二次翻修风险无显著关联(HR 0.74,95%CI 0.215-2.546,p=0.535)。
- 总重建长度、BMI及年龄与二次翻修生存率无显著关联。
临床怎么用
- 对首次假体并发症翻修患者应告知二次并发症高风险,并加强术后随访。
- 尽可能采用术前放疗而非术后放疗以降低二次并发症风险。
- 对合并糖尿病的患者应加强围手术期管理及假体并发症监测。
局限性
- 回顾性单中心研究,仅使用单一设计假体系统,外推需谨慎。
- 证据等级为III级治疗性研究。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Endoprosthetic reconstruction of massive bone defects has become the reconstruction method of choice after limb-sparing resection of primary malignant tumors of the long bones. Given the improved survival rates of patients with extremity bone sarcomas, an increasing number of patients survive but have prosthetic complications over time. Several studies have reported on the outcome of first endoprosthetic complications. However, no comprehensive data, to our knowledge, are available on the likelihood of an additional complication and the associated risk factors, despite the impact of this issue on the affected patients. QUESTIONS/PURPOSES: (1) What are the types and timing of complications and the implant survivorship free from revision after the first complication? (2) Does survivorship free from repeat revision for a second complication differ by anatomic sites? (3) Is the type of first complication associated with the risk or the type of a second complication? (4) Are patient-, tumor-, and treatment-related factors associated with a higher likelihood of repeat revision? METHODS: Between 1993 and 2015, 817 patients underwent megaprosthetic reconstruction after resection of a tumor in the long bones with a single design of a megaprosthetic system. No other prosthetic system was used during the study period. Of those, 75% (616 of 817) had a bone sarcoma. Seventeen patients (3%) had a follow-up of less than 6 months, 4.5% (27 of 599) died with the implant intact before 6 months and 43% (260 of 599 patients) underwent revision. Forty-three percent of patients (260 of 599) experienced a first prosthetic complication during the follow-up period. Ten percent of patients (26 of 260) underwent amputation after the first complication and were excluded from further analysis. Second complications were classified using the classification of Henderson et al. to categorize surgical results. Briefly, this system categorizes complications as wound dehiscence (Type 1); aseptic loosening (Type 2); implant fractures or breakage and periprosthetic fracture (Type 3); infection (Type 4); and tumor progression (Type 5). Implant survival curves were calculated with the Kaplan-Meier method and compared using the log-rank test. Hazard ratios (HR) were estimated with their respective 95% CIs in multivariate Cox regression models. RESULTS: A second complication occurred in 49% of patients (115 of 234) after a median of 17 months (interquartile range [IQR] 5 to 48) after the surgery for the first complication. The time to complication did not differ between the first (median 16 months; IQR 5 to 57) and second complication (median 17 months; IQR 5 to 48; p = 0.976). The implant survivorship free from revision surgery for a second complication was 69% (95% CI 63 to 76) at 2 years and 46% (95% CI 38 to 53) at 5 years. The most common mode of second complication was infection 39% (45 of 115), followed by structural complications with 35% (40 of 115). Total bone and total knee reconstructions had a reduced survivorship free from revision surgery for a second complication at 5 years (HR 2.072 [95% CI 1.066 to 3.856]; p = 0.031) compared with single joint replacements. With the numbers we had, we could not show a difference between the survivorship free of revision for a second complication based on the type of the first complication (HR 0.74 [95% CI 0.215 to 2.546]; p = 0.535). We did not detect an association between total reconstruction length, patient BMI, and patient age and survivorship free from revision for a second complication. Patients had a higher risk of second complications after postoperative radiotherapy (HR 1.849 [95% CI 1.092 to 3.132]; p = 0.022) but not after preoperative radiotherapy (HR 1.174 [95% CI 0.505 to 2.728]; p = 0.709). Patients with diabetes at the time of initial surgery had a reduced survivorship free from revision for a second complication (HR 4.868 [95% CI 1.497 to 15.823]; p = 0.009). CONCLUSIONS: Patients who undergo revision to treat a first megaprosthetic complication must be counseled regarding the high risk of future complications. With second complications occurring relatively soon after the first revision, regular orthopaedic follow-up visits are advised. Preoperative rather than postoperative radiotherapy should be performed when possible. Future studies should evaluate the effectiveness of different approaches in treating complications considering implant survivorship free of revision for a second complication. LEVEL OF EVIDENCE: Level III, therapeutic study.
引用
- Theil C, Röder J, Gosheger G, et al. What is the Likelihood That Tumor Endoprostheses Will Experience a Second Complication After First Revision in Patients With Primary Malignant Bone Tumors And What Are Potential Risk Factors? Clin Orthop Relat Res. 2019. PMID: 31764339. doi:10.1097/CORR.0000000000000955
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。